Stock NECLIFE NECTAR LIFESCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nectar Lifesciences Limited Bombay S.E.

Equities

NECLIFE

INE023H01027

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:51 2024-05-31 EDT 		5-day change 1st Jan Change
31.79 INR +0.44% Intraday chart for Nectar Lifesciences Limited -5.08% -1.15%
05-15 Nectar Lifesciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
05-15 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 5,887 3,869 2,198 4,171 5,393 3,577
Enterprise Value (EV) 1 15,339 12,685 9,771 12,945 13,810 10,936
P/E ratio 11.3 x 8.14 x 6.91 x -5.69 x 21.5 x -14.8 x
Yield 0.19% 0.29% 0.51% - - -
Capitalization / Revenue 0.31 x 0.14 x 0.09 x 0.27 x 0.32 x 0.23 x
EV / Revenue 0.82 x 0.46 x 0.41 x 0.84 x 0.83 x 0.72 x
EV / EBITDA 6.48 x 4.8 x 4.44 x 11.7 x 8.71 x 20.3 x
EV / FCF -20.5 x 14.5 x 7.5 x 6.19 x -28.1 x 42.1 x
FCF Yield -4.88% 6.88% 13.3% 16.2% -3.56% 2.37%
Price to Book 0.56 x 0.35 x 0.19 x 0.39 x 0.5 x 0.34 x
Nbr of stocks (in thousands) 224,261 224,261 224,261 224,261 224,261 224,261
Reference price 2 26.25 17.25 9.800 18.60 24.05 15.95
Announcement Date 18-08-23 19-08-22 20-08-14 21-08-24 22-08-24 23-08-11
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 18,763 27,829 23,664 15,433 16,689 15,237
EBITDA 1 2,366 2,645 2,201 1,102 1,586 539.5
EBIT 1 1,723 2,012 1,593 499.9 1,016 -51.73
Operating Margin 9.18% 7.23% 6.73% 3.24% 6.09% -0.34%
Earnings before Tax (EBT) 1 626.8 588.2 374.7 -847.7 340.8 -424.2
Net income 1 522.7 476 317.9 -732.6 250.5 -241.8
Net margin 2.79% 1.71% 1.34% -4.75% 1.5% -1.59%
EPS 2 2.330 2.120 1.418 -3.270 1.117 -1.080
Free Cash Flow 1 -749.1 873 1,303 2,091 -492.1 259.6
FCF margin -3.99% 3.14% 5.5% 13.55% -2.95% 1.7%
FCF Conversion (EBITDA) - 33.01% 59.18% 189.7% - 48.12%
FCF Conversion (Net income) - 183.4% 409.77% - - -
Dividend per Share 2 0.0500 0.0500 0.0500 - - -
Announcement Date 18-08-23 19-08-22 20-08-14 21-08-24 22-08-24 23-08-11
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 9,452 8,816 7,573 8,774 8,417 7,359
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.995 x 3.333 x 3.441 x 7.959 x 5.308 x 13.64 x
Free Cash Flow 1 -749 873 1,303 2,091 -492 260
ROE (net income / shareholders' equity) 5.06% 4.4% 2.84% -6.67% 2.33% -2.25%
ROA (Net income/ Total Assets) 4.06% 4.63% 3.73% 1.22% 2.66% -0.14%
Assets 1 12,873 10,274 8,521 -59,846 9,425 171,389
Book Value Per Share 2 47.20 49.30 50.70 47.40 48.50 47.50
Cash Flow per Share 2 0.4200 0.9500 0.9500 1.140 0.7900 0.7800
Capex 1 332 381 548 312 250 301
Capex / Sales 1.77% 1.37% 2.31% 2.02% 1.5% 1.97%
Announcement Date 18-08-23 19-08-22 20-08-14 21-08-24 22-08-24 23-08-11
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+15.91% 41.97B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.40% 22.34B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.48% 15.25B
CIPLA LIMITED Stock Cipla Limited
+16.12% 14B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+45.12% 12.06B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.58% 6.8B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.18% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NECLIFE Stock
  4. NECLIFE Stock
  5. Financials Nectar Lifesciences Limited